Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLIGHT: Mycophenolate Mofetil for First-Line Treatment of ITP
NCT03156452Phase 3Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Oct 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate mofetil in immune thrombocytopenia (ITP) (2 arms), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Time from randomisation to treatment failure at 1 year. Started Oct 2017; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03156452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156452.